Ultimovacs Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Ultimovacs heeft een totaal eigen vermogen van NOK191.0M en een totale schuld van NOK0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk NOK215.8M en NOK24.8M.

Belangrijke informatie

Verhouding schuld/eigen vermogen

NOK 0

Schuld

Rente dekkingsratio	n/a
Contant	NOK 131.00m
Aandelen	NOK 191.01m
Totaal verplichtingen	NOK 24.78m
Totaal activa	NOK 215.79m

Recente financiële gezondheidsupdates

Here's Why We're Not At All Concerned With Ultimovacs' (OB:ULTI) Cash Burn Situation

Jul 27

We're Hopeful That Ultimovacs (OB:ULTI) Will Use Its Cash Wisely

Mar 23

Recent updates

Companies Like Ultimovacs (OB:ULTI) Can Afford To Invest In Growth

Feb 21

Ultimovacs (OB:ULTI) Is In A Strong Position To Grow Its Business

Oct 26

Companies Like Ultimovacs (OB:ULTI) Are In A Position To Invest In Growth

Oct 05

Ultimovacs (OB:ULTI) Is In A Good Position To Deliver On Growth Plans

May 19

Here's Why We're Not At All Concerned With Ultimovacs' (OB:ULTI) Cash Burn Situation

Jul 27

We're Hopeful That Ultimovacs (OB:ULTI) Will Use Its Cash Wisely

Mar 23

Have Insiders Sold Ultimovacs ASA (OB:ULTI) Shares Recently?

Feb 13

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( NOK140.1M ) ULTI } overtreffen de korte termijn passiva ( NOK12.3M ).

Langlopende schulden: De kortetermijnactiva ULTI ( NOK140.1M ) overtreffen de langetermijnschulden ( NOK12.5M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: ULTI is schuldenvrij.

Schuld verminderen: ULTI had 5 jaar geleden geen schulden.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: ULTI heeft minder dan een jaar aan cash runway op basis van de huidige vrije kasstroom.

Voorspelling contante baan: ULTI heeft voldoende kasruimte voor 1.5 jaar als de vrije kasstroom blijft dalen met een historisch percentage van 22 % per jaar.

Ultimovacs Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Companies Like Ultimovacs (OB:ULTI) Can Afford To Invest In Growth

Ultimovacs (OB:ULTI) Is In A Strong Position To Grow Its Business

Companies Like Ultimovacs (OB:ULTI) Are In A Position To Invest In Growth

Ultimovacs (OB:ULTI) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not At All Concerned With Ultimovacs' (OB:ULTI) Cash Burn Situation

We're Hopeful That Ultimovacs (OB:ULTI) Will Use Its Cash Wisely

Recent updates

Ultimovacs ASA Announces Publication of Phase II FOCUS Trial Results on MedRxiv

New major risk - Market cap size

Ultimovacs ASA Announces Resignation of Ketil Fjerdingen as Deputy Board Member

Ultimovacs ASA Announces Topline Data from FOCUS Phase II Trial of UV1 Combined with Pembrolizumab in Patients with Metastatic or Recurrent Head and Neck Cancer

Ultimovacs Asa Announces Poster Presentation of Nipu Phase II Trial Update At Upcoming ESMO Congress 2024

Ultimovacs Asa Provides Update from Phase I Study in Malignant Melanoma

No longer forecast to breakeven

New major risk - Revenue and earnings growth

Ultimovacs ASA Implements Operational Adjustments to Support Continuous Advancement of the UV1 Vaccine Phase II Program

Price target decreased by 8.6% to kr155

New minor risk - Market cap size

Ultimovacs Announces Topline Results from INITIUM Study Evaluating UV1 Vaccination Added to Ipilimumab and Nivolumab in Patients with Unresectable or Metastatic Malignant Melanoma

New minor risk - Share price stability

Companies Like Ultimovacs (OB:ULTI) Can Afford To Invest In Growth

Ultimovacs Receives FDA Fast Track Designation for UV1 Cancer Vaccine for the Treatment of Patients with Unresectable Mesothelioma

Ultimovacs ASA Updates Timeline for Reporting on Randomized UV1 Phase II Trial Initium in Malignant Melanoma

Ultimovacs ASA to Report Q4, 2024 Results on Feb 13, 2025

Insufficient new directors

Ultimovacs ASA Announces Resignation of Aitana Peire from Board of Directors

Ultimovacs ASA Announces Resignation of Aitana Peire from Board of Directors

Chief Executive Officer recently bought kr57k worth of stock

No longer forecast to breakeven

Ultimovacs ASA Announces Completion of Patient Enrollment in Supplementary Study to INITium, UV1 Phase II Trial in Malignant Melanoma

Ultimovacs ASA Announces Protocol Amendment in UV1 Phase II Study INITIUM in Malignant Melanoma, Enabling Data Readout in First Half of 2024

Ultimovacs (OB:ULTI) Is In A Strong Position To Grow Its Business

Ultimovacs ASA Announces Full Dataset from the NIPU Clinical Trial (Nct04300244) Presented At the ESMO Congress 2023 in Madrid

Ultimovacs ASA Announces the Results from the NIPU clinical trial (NCT04300244)

New minor risk - Share price stability

Ultimovacs Provides 4-Year Update from Phase I Study in Malignant Melanoma: Demonstrating Sustained Long-Term Overall Survival in Patients Treated with Uv1 Cancer Vaccine

Ultimovacs ASA Receives FDA Orphan Drug Designation for the Uv1 Cancer Vaccine for Treatment of Mesothelioma

Ultimovacs ASA Announces the Results from Uv1 Phase Ii Clinical Trial Nipu in Malignant Mesothelioma Will Be Presented At the Esmo Congress 2023

Ultimovacs Announces Completed Enrollment in FOCUS Phase II Clinical Trial of UV1 in Head and Neck Cancer Patients

Ultimovacs ASA Announces Publication in Clinical Cancer Research of the UV1-103 Phase I Malignant Melanoma Trial Results

Ultimovacs Provides 3-Year Update from Phase I Study in Malignant Melanoma: Results Confirm Strong Overall Survival in Patients Treated with UV1 Cancer Vaccine

New minor risk - Share price stability

Ultimovacs ASA Provides Update on Phase II NIPU Trial Evaluating UV1 in Second-Line Patients with Malignant Leural Mesothelioma

No longer forecast to breakeven

Ultimovacs ASA Announces Completion of Patient Recruitment in NIPU Phase II Clinical Trial of UV1 in Mesothelioma

Ultimovacs ASA, Annual General Meeting, Apr 18, 2024

Ultimovacs ASA Announces Cemiplimab to Replace Pembrolizumab in V1 Phase II LUNGVAC Trial

Ultimovacs ASA Completes Last Patient Enrollment in Phase I TENDU Trial in Prostate Cancer

Chief Executive Officer recently bought kr145k worth of stock

Forecast to breakeven in 2023

No independent directors

No longer forecast to breakeven

Ultimovacs Announces First Patient Randomized in Phase II LUNGVAC Trial of UV1 in Non-Small Cell Lung Cancer (NSCLC)

Ultimovacs Asa Announces New Uv1 Data Showing Enhanced Efficacy Including in Hard-To-Treat Cancer Patients, Supporting Broad Utility

Ultimovacs Asa Announces New Uv1 Data Showing Enhanced Efficacy Including in Hard-To-Treat Cancer Patients, Supporting Broad Utility

Ultimovacs ASA Announces Positive Three-Year Results of 71% Overall Survival Rate in Cohort 1 of UV1-103 Study in Metastatic Malignant Melanoma

Companies Like Ultimovacs (OB:ULTI) Are In A Position To Invest In Growth

Ultimovacs ASA Announces Publication of Phase I Melanoma Trial Data in Journal of Translational Medicine

Chief Executive Officer recently bought kr134k worth of stock

Price target increased to kr151

Ultimovacs ASA Expands High Dose Cohort Size in Tendu Phase I Prostate Cancer Trial After Safety Review

Ultimovacs Completes Patient Recruitment in INITIUM Phase II Trial of UV1 in Malignant Melanoma

Ultimovacs ASA Announces UV1 Cancer Vaccine Shows Strong Overall Survival in Malignant Melanoma Phase I Trial

Ultimovacs (OB:ULTI) Is In A Good Position To Deliver On Growth Plans

Ultimovacs Announces Presentation of UV1 Immune Monitoring Data At Cancer Immunotherapy Annual Meeting

Price target increased to kr151

No independent directors

Ultimovacs ASA Approves Board and Committee Changes

Ultimovacs Presents TET Platform Pre-Clinical Data at AACR 2022 Supporting Clinical Development

Chief Executive Officer recently bought kr94k worth of stock

Ultimovacs ASA Completes Treatment of the Second Dose Cohort in the Phase I TENDU Trial

Ultimovacs ASA Announces First Patient Enrolled in Phase II DOVACC Trial of UV1 in Advanced Ovarian Cancer

Chief Executive Officer recently bought kr228k worth of stock

Ultimovacs Asa Announces Further Positive Topline Results from Phase I Uv1 Cancer Vaccine Combination Study in Metastatic Melanoma

Ultimovacs Announces First Patient Enrolled in Phase II Focus Trial of UV1 in Head-And-Neck Cancer

Here's Why We're Not At All Concerned With Ultimovacs' (OB:ULTI) Cash Burn Situation